temozolomide has been researched along with carmustine in 153 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.31) | 18.7374 |
| 1990's | 13 (8.50) | 18.2507 |
| 2000's | 65 (42.48) | 29.6817 |
| 2010's | 68 (44.44) | 24.3611 |
| 2020's | 5 (3.27) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Bakalara, N; Clarion, L; Filippini, D; Hirlemann, MH; Jacquard, C; Lecouvey, M; Loiseau, S; Pirat, JL; Sainte-Catherine, O; Virieux, D; Volle, JN | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dive, C; Watson, JV; Workman, P | 1 |
| Broggini, M; Catapano, CV; Citti, L; D'Incalci, M; Erba, E; Mariani, L; Ponti, M | 1 |
| Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC | 1 |
| Grever, MR; Koutsoukos, AD; Moore, TD; Plowman, J; Rubinstein, LV; Waud, WR | 1 |
| Dolan, ME; Mitchell, RB | 1 |
| May, BL; Newlands, ES; Porteus, JK; Wedge, SR | 1 |
| Newlands, ES; Wedge, SR | 1 |
| Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Gerson, SL; Liu, L; Markowitz, S | 1 |
| Ashby, J; Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Margison, GP; Rafferty, JA; Tinwell, H | 1 |
| Fei, ZL; Gallo, JM; Klein-Szanto, A; Ma, J | 1 |
| Davis, BM; Gerson, SL; Liu, L; Reese, JS | 1 |
| Allan, JM; Broekhof, JL; Carls, NH; Donker, I; Engelward, BP; Glassner, BJ; Hampson, RJ; Hersmus, R; Hickman, MJ; Hoeijmakers, JH; Roth, RB; Samson, LD; Warren, HB; Weeda, G; Wu, MM | 1 |
| Chatterjee, S; Gerson, SL; Liu, L; Taverna, P; Whitacre, CM | 1 |
| Gerson, SL; Koç, ON; Reese, JS | 1 |
| Prados, MD | 1 |
| Cai, Y; Dolan, ME; Ludeman, SM; Pegg, AE; Wu, MH; Xu-Welliver, M | 1 |
| Bocangel, DB; Kokkinakis, DM; Moschel, RC; Pegg, AE; Schold, SC | 1 |
| Bosik, ME; Chang, SM; Fink, KL; Fulton, D; Kuhn, JG; Mehta, MP; Prados, MD; Robins, HI; Schold, SC; Spence, AM | 1 |
| Frenkel, EP; Han, Q; Hoffman, RM; Kokkinakis, DM; Schold, SC; Tan, Y; Wick, JB; Xu, M | 1 |
| Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW | 1 |
| Prados, M | 1 |
| Bardenheuer, W; Flasshove, M; Jansen, M; Moritz, T; Seeber, S; Sorg, UR | 1 |
| Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| Dolan, ME; Long, L | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Blank, A; Bobola, MS; Haroldson, PD; Huynh, MB; Kolstoe, DD; Schoeler, KD; Silber, JR | 1 |
| Li, Y; McClay, EF | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M | 1 |
| Bonmassar, E; D'Atri, S; Falcinelli, S; Fuggetta, MP; Jiricny, J; Marra, G; Pagani, E; Pepponi, R | 1 |
| Ariza, A; Balaña, C; Ballester, R; Mendez, P; Ramirez, JL; Rosell, R; Roussos, Y; Sanchez, JJ; Sarries, C; Taron, M | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Ahmed, MM; Chendil, D; Kokkinakis, DM; Moschel, RC; Pegg, AE | 1 |
| Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I | 1 |
| Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK | 1 |
| Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR | 1 |
| Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK | 1 |
| Ashley, DL; Cher, L; Rosenthal, MA | 1 |
| Aguirre-Cruz, L; Crinière, E; Delattre, JY; Duprez, A; Golmard, JL; Kujas, M; Leuraud, P; Marie, Y; Medioni, J; Poupon, MF; Sanson, M; Taillandier, L | 1 |
| Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L | 1 |
| Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ | 1 |
| Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R | 1 |
| Chinnasamy, D; Chinnasamy, N; Fairbairn, LJ; Hanson, JP; Margison, GP; Neuenfeldt, J; Treisman, JS | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Cairncross, JG; Mymryk, JS; Xu, GW | 2 |
| Blank, A; Bobola, MS; Ellenbogen, RG; Geyer, JR; Goff, RD; Silber, JR | 1 |
| Cai, S; Cooper, RJ; Ferkowicz, MJ; Hartwell, JR; Kelley, MR; Pollok, KE; Xu, Y | 1 |
| Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC | 1 |
| Ashby, L; LaRocca, R; Ryken, T | 1 |
| Duncan, T; Lindahl, T; Paik, J; Sedgwick, B | 1 |
| Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX | 1 |
| Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J | 1 |
| Covas, DT; Davis, BM; Encell, LP; Fontes, AM; Gerson, SL; Lingas, K; Loeb, LA; Pegg, AE; Zago, MA | 1 |
| Reardon, DA | 1 |
| Audra, P; Cartalat-Carel, S; Colin, P; Ducray, F; Gaucherand, P; Honnorat, J; Mahla, K; Pelissou-Guyotat, I; Trouillas, P | 1 |
| Delaney, SM; Dolan, ME; Hansen, RJ; Nagasubramanian, R; Samson, LD | 1 |
| Chen, CC; D'Andrea, A; Taniguchi, T | 1 |
| Barcia, JA; Barcia-Mariño, C; Gallego, JM | 1 |
| Ducray, F; Honnorat, J | 1 |
| Brandes, AA; Franceschi, E; Tosoni, A | 1 |
| DeAngulo, G; Heimberger, AB; Hussain, SF; Jordan, JT; Prabhu, SS; Sun, W | 1 |
| Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Price, A; Rogers, G; Somerville, M; Stein, K | 1 |
| Aoki, T; Hashimoto, N; Matsutani, M | 1 |
| Kleinberg, LR; Lin, SH | 1 |
| Mitchell, SB; Pan, E; Tsai, JS | 1 |
| Ogawa, M; Ueda, T; Yamauchi, T | 1 |
| Geisert, EE; Kang, GS; Kirichenko, OV; Miller, DD; Mohler, ML; Orr, WE; Patil, R; Wang, XD | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Adumala, RR; Altaha, R; Crowell, EB; Hobbs, GR; Vinjamuri, M | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Gathinji, M; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, AR; Than, K; Weingart, JD | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD | 1 |
| Heymann, S; Karamanoukian, D; Noël, G; Quetin, P; Schott, R | 1 |
| Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K | 1 |
| Choi, U; Clevenger, JR; Donahue, RE; Dunbar, CE; Kang, E; Krouse, A; Larochelle, A; Loktionova, NA; Malech, HL; Metzger, M; Naumann, N; Persons, D; Shou, Y; Sorrentino, BP; Stewart, C | 1 |
| Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ | 1 |
| Nishikawa, R | 1 |
| Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A | 1 |
| Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A | 1 |
| Brem, H; McGirt, MJ | 1 |
| Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH | 1 |
| Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E | 1 |
| Emmerich, J; Giménez-Pando, J; Gómez-González, E; Márquez-Rivas, J; Ollero-Ortiz, A; Quiroga-Cantero, E; Ramirez, G; Rivas, E | 1 |
| Baumann, RP; Ishiguro, K; Penketh, PG; Sartorelli, AC; Shyam, K; Zhu, YL | 1 |
| Kim, JH; Kim, ST; Kim, WS; Kong, DS; Kwon, KH; Lee, JI; Lim, DH; Nam, DH; Park, K; Suh, YL | 1 |
| Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M | 1 |
| Chen, C; Damek, DM; Franklin, W; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Olsen, C; Rusthoven, KE; Waziri, A | 1 |
| Chansriwong, P; Sirisinha, T | 1 |
| Boyer, P; Dufour, P; Fischer-Lokou, D; Froelich, S; Gaub, MP; Kehrli, P; Maitrot, D; Noël, G; Schott, R | 1 |
| Achawal, S; Dixit, S; Hingorani, M; Scott, I | 1 |
| Stummer, W; van den Bent, MJ; Westphal, M | 1 |
| Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A | 1 |
| Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Bernaudin, M; Chapon, F; Colin, P; Diebold, MD; Dugué, AE; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Menei, P; Peruzzy, P; Vital, A | 1 |
| Bouchekoua, M; Hieu, PD; Malhaire, JP; Miglierini, P; Pradier, O; Rousseau, B | 1 |
| Breneman, JC; Gerena-Lewis, M; McPherson, CM; Warnick, RE | 1 |
| Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP | 1 |
| Barr, JG; Grundy, PL | 1 |
| Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A | 1 |
| Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K | 1 |
| Allgayer, H; Fruehauf, S; Heckmann, D; Laufs, S; Maier, P; Spier, I; Wenz, F; Zeller, WJ; Zucknick, M | 1 |
| Payne, CA; Safdar, S; Taite, LJ; Tu, NH | 1 |
| Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H | 1 |
| Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E | 1 |
| Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL | 1 |
| Braunsdorf, WE; Giese, A; Gutenberg, A; Lumenta, CB; Mehdorn, HM; Sabel, M; Westphal, M | 1 |
| Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M | 1 |
| Antonietti, P; Balss, J; Capper, D; Frank, J; Kögel, D; Mohrenz, IV; Mukrowsky, A; Pusch, S; Seifert, V; Senft, C; Voigt, S; von Deimling, A; Weissert, S | 1 |
| Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
| Chamberlain, MC | 1 |
| Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M | 1 |
| Bardin, AL; Carson-Walter, E; Cui, W; Folts, CJ; Noble, M; Stevens, BM; Vescovi, A; Walter, K | 1 |
| Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY | 1 |
| Beveridge, RD; Carroll, TA; Collis, SJ; Cox, A; Depondt, ML; Fernando, M; Jellinek, D; Kriplani, DH; Myers, KN; Patil, AA; Roylance, A; Sayal, P | 1 |
| Hay, JW; Messali, A; Villacorta, R | 1 |
| Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR | 1 |
| Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF | 1 |
| Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM | 1 |
| Banković, J; Dinić, J; Hadžić, S; Isaković, A; Paunović, V; Pešić, M; Podolski-Renić, A; Stanković, T; Stojković, S; Tanić, N | 1 |
| Brem, H; Burger, P; Chaichana, KL; Gallia, GL; Grossman, R; Olivi, A; Quiñones-Hinojosa, A; Sidransky, D; Soudry, E; Tyler, B; Weingart, J; Ye, X | 1 |
| Chakrabarti, M; Ray, SK | 1 |
| Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ | 1 |
| Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X | 1 |
| Borkowska, P; Fila-Daniłow, A; Kowalczyk, M; Kowalski, J; Paul-Samojedny, M; Pudełko, A; Suchanek-Raif, R | 1 |
| Ashby, LS; Smith, KA; Stea, B | 1 |
| Hirose, Y; Ohba, S | 1 |
| Azzalin, A; Buffo, A; Garello, F; Magrassi, L; Nato, G; Parmigiani, E | 1 |
| Cappabianca, P; Cavallo, LM; Frio, F; Grujicic, D; Illic, R; Lavrnic, S; Milicevic, M; Milosevic, S; Nikitovic, M; Raicevic, S; Savic, D; Solari, D; Somma, T | 1 |
| Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A | 1 |
| Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J | 1 |
| Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M | 1 |
| Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
| Graham, GT; Haddad, BR; Pannkuk, EL; Riggins, RB; Rone, JD; Tiek, DM | 1 |
| Carlan da Silva, MC; de Aguiar, RB; Dos Santos, CJ; Ferreira Castro, FL; Menezes, IG; Nevels, M; Paulus, C; Santos, AC | 1 |
| García-Taboada, E; Guzmán, M; Hernández-Tiedra, S; López-Valero, I; Lorente, M; Salazar-Roa, M; Sepúlveda, JM; Torres, S; Velasco, G | 1 |
| Chen, C; Han, G; Li, Y; Liu, J; Wang, L; Yue, Z | 1 |
| Brem, H; Cecia, A; Doglioli, M; Domb, AJ; Gorelick, N; Kumar, A; Langer, R; Peters, M; Rottenberg, Y; Serra, R; Shapira-Furman, T; Tagliaferri, V; Tyler, B | 1 |
| Appay, R; Autran, D; Barrie, M; Boucard, C; Campello, C; Chinot, O; Dufour, H; Figarella-Branger, D; Graillon, T; Loundou, A; Matta, M; Monserrat, C; Padovani, L; Petrirena, G; Tabouret, E | 1 |
| Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M | 1 |
| Bacolod, MD; Barany, F | 1 |
| Imai, R; Sasaki, H | 1 |
| Chai, M; Chen, S; Gu, G; He, H; Heo, DN; Qiu, Q; She, D; Wang, D; Wang, J; Yin, B | 1 |
| Awortwe, C; Cascorbi, I; Kaehler, M; Majchrzak-Celińska, A; Nagel, I; Radtke, L; Sebens, S; Vater, I | 1 |
| Bruns, J; Chen, D; Clancy, A; Nadella, J; Stealey, S; Timperman, A; Zhang, Y; Zustiak, SP | 1 |
17 review(s) available for temozolomide and carmustine
| Article | Year |
|---|---|
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Temozolomide; Topotecan | 2000 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioma; Humans; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Quality of Life; Temozolomide | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Genetic Therapy; Glioblastoma; Humans; Immunotherapy; Polyesters; Temozolomide | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Delayed-Action Preparations; Glioma; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Temozolomide | 2008 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Lomustine; Myelodysplastic Syndromes; Neoplasms, Second Primary; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Drug Implants; Glioblastoma; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Polyesters; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Temozolomide; Venous Thromboembolism; Young Adult | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2011 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Evidence-Based Medicine; Glioblastoma; Humans; Temozolomide | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Glioblastoma; Health Care Costs; Humans; Quality-Adjusted Life Years; Temozolomide | 2014 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Drug Implants; Glioblastoma; Humans; Middle Aged; Neoplasm Grading; Polyesters; Temozolomide; United States; United States Food and Drug Administration | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dosage Forms; Glioma; Humans; Neoplasm Recurrence, Local; Neurosurgical Procedures; Quality of Life; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
21 trial(s) available for temozolomide and carmustine
| Article | Year |
|---|---|
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Half-Life; Humans; Maximum Tolerated Dose; Temozolomide | 2000 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Implants; Drug Synergism; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Safety; Supratentorial Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2001 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence Intervals; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Temozolomide | 2004 |
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neutrophils; Temozolomide | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Humans; Male; Middle Aged; Pilot Projects; Temozolomide | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Temozolomide | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Child; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lomustine; Male; Middle Aged; Neoplasm Staging; Neoplasms, Neuroepithelial; Neoplasms, Radiation-Induced; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine; Young Adult | 2010 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Prospective Studies; Temozolomide | 2012 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Neurosurgical Procedures; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide | 2013 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Therapy; Glioblastoma; Guanine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Prospective Studies; Temozolomide; Tumor Suppressor Proteins | 2014 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Postoperative Period; Prognosis; Prospective Studies; Radiotherapy Dosage; Survival Rate; Temozolomide | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Electric Stimulation Therapy; Europe; Female; Glioblastoma; Humans; Israel; Maintenance Chemotherapy; Male; Middle Aged; Republic of Korea; Temozolomide; United States; Young Adult | 2015 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Follow-Up Studies; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2016 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Implants; Glioblastoma; Humans; Japan; Medical Oncology; Temozolomide | 2019 |
115 other study(ies) available for temozolomide and carmustine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Survival; Cyclic P-Oxides; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Organophosphonates; Phosphorous Acids; Rats; Stereoisomerism; Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esterases; Female; Flow Cytometry; Mammary Neoplasms, Experimental; Mesylates; Mice; Nitrogen Mustard Compounds; Spectrometry, Fluorescence; Temozolomide; Thiepins; Tumor Cells, Cultured | 1989 |
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Leukemia L1210; Methylation; Methyltransferases; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 1987 |
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Temozolomide; Transplantation, Heterologous | 1995 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Methyltransferases; Mice; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1994 |
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Dacarbazine; Humans; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1993 |
Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Guanine; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1996 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Dacarbazine; Glioblastoma; Guanine; Humans; Kinetics; Methyltransferases; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured | 1996 |
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Methylation; Methyltransferases; Microsatellite Repeats; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Carmustine; Cell Division; Dacarbazine; Drug Synergism; Female; Guanine; Hematopoietic Stem Cells; Male; Mice; Temozolomide | 1997 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, Antisense; Endothelial Growth Factors; Genetic Vectors; Glioma; Humans; Lymphokines; Male; Neoplasm Proteins; Neovascularization, Pathologic; Rats; Rats, Nude; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Combinations; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred C3H; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic; Transfection; Tumor Cells, Cultured | 1999 |
DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinogens; Carmustine; Dacarbazine; Genotype; Hematopoietic System; Liver; Methylnitronitrosoguanidine; Mice; Mice, Knockout; Mitomycin; Models, Biological; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin; Temozolomide | 1999 |
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 1999 |
Human mesenchymal stem cells provide stromal support for efficient CD34+ transduction.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Cytokines; Dacarbazine; Drug Resistance, Multiple; Genetic Vectors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Mesoderm; Monocytes; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Retroviridae; Signal Transduction; Stem Cells; Stromal Cells; Temozolomide | 1999 |
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; CHO Cells; Cricetinae; Cyclophosphamide; Dacarbazine; Drug Interactions; Enzyme Inhibitors; Guanine; Mutagenicity Tests; Mutagens; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon-Sulfur Lyases; Carmustine; Choline; Dacarbazine; Diet; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Methionine; Mice; Mice, Inbred BALB C; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Temozolomide; Xenograft Model Antitumor Assays | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Gene Transfer Techniques; Glioma; Humans; Inhibitory Concentration 50; Sensitivity and Specificity; Temozolomide; Transcription Factors; Tumor Cells, Cultured | 2001 |
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
Topics: Alkylating Agents; Alkylation; Animals; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Dacarbazine; DNA Damage; DNA, Complementary; Drug Resistance; Genetic Vectors; Hematopoietic Stem Cells; Humans; Lomustine; Mice; Moloney murine leukemia virus; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Fusion Proteins; Retroviridae; Sarcoma Viruses, Murine; Spleen Focus-Forming Viruses; Temozolomide; Terminal Repeat Sequences; Transfection | 2001 |
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
Topics: Antineoplastic Agents; Biotransformation; Carmustine; Cytochrome P-450 Enzyme System; Cytosol; Dacarbazine; DNA Repair; Guanine; Humans; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Temozolomide | 2001 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; Dacarbazine; DNA Adducts; DNA Damage; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Induction; Glioblastoma; Humans; Hypochlorous Acid; Methyl Methanesulfonate; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2002 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sulfones; Telomerase; Temozolomide; Transfection; Tumor Cells, Cultured | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Melanoma; Temozolomide; Tumor Cells, Cultured | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; CpG Islands; Dacarbazine; Disease Progression; DNA; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 2003 |
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; Deoxyguanosine; DNA Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; O(6)-Methylguanine-DNA Methyltransferase; Pancreatic Neoplasms; Temozolomide; Time Factors | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarbazine; Glioblastoma; Humans; Ifosfamide; Loss of Heterozygosity; Mice; Mice, Nude; Mutation; Oligodendroglioma; Temozolomide; Xenograft Model Antitumor Assays | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Methylation; DNA Repair; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2004 |
Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide.
Topics: Antigens, CD34; Blotting, Western; Carmustine; Cell Line; Colony-Forming Units Assay; Dacarbazine; DNA Primers; Flow Cytometry; Gene Expression Regulation, Enzymologic; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Temozolomide; Transduction, Genetic; Transgenes; Tumor Cells, Cultured | 2004 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Drug Interactions; Glioma; Humans; Temozolomide; Thiazoles; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain; Carmustine; Cell Survival; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Guanine; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Tumor Cells, Cultured | 2005 |
Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Nucleus; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Methyl Methanesulfonate; Mitochondria; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
Topics: Antineoplastic Agents; Astrocytoma; Blotting, Western; Carmustine; Cell Cycle; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Gene Silencing; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2005 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Genetic Vectors; HeLa Cells; Humans; Methyl Methanesulfonate; Ovarian Neoplasms; RNA Interference; RNA, Small Interfering; Temozolomide; Ultraviolet Rays; Uterine Cervical Neoplasms | 2005 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Glioblastoma; Humans; Hyaluronan Receptors; Intracellular Signaling Peptides and Proteins; NF-kappa B; Nuclear Proteins; Proteins; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2006 |
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Topics: Alkylating Agents; Carmustine; Dacarbazine; Drug Resistance; Genetic Engineering; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Signal Transduction; Temozolomide | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamazepine; Carmustine; Case Management; Cesarean Section; Chemotherapy, Adjuvant; Cranial Irradiation; Craniotomy; Dacarbazine; Female; Frontal Lobe; Glioblastoma; Humans; Infant, Newborn; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Paresis; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Temozolomide; Temporal Lobe | 2006 |
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Topics: Alkylating Agents; Animals; Carmustine; Cell Line, Tumor; Cyclophosphamide; Dacarbazine; Guanine; Male; Mice; Mice, Transgenic; Mutagenicity Tests; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group F Protein; Fanconi Anemia Complementation Group Proteins; Glioma; Guanine; Humans; Protein Processing, Post-Translational; RNA Interference; RNA, Small Interfering; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins; Ubiquitins | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Drug Implants; Fatal Outcome; Female; Glioblastoma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Temozolomide; Temporal Lobe; Ventriculostomy | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Temozolomide | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL22; Chemokines; Chemotaxis, Leukocyte; Cytoplasm; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma; Humans; Receptors, CCR2; Receptors, CCR4; T-Lymphocytes, Regulatory; Temozolomide | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Implants; Glioblastoma; Humans; Kaplan-Meier Estimate; Radiotherapy; Retrospective Studies; Temozolomide | 2008 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmium Chloride; Carmustine; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Mismatch Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Hydroxylamines; Nimustine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioma; Male; Rats; Rats, Sprague-Dawley; Temozolomide; Tetrahydroisoquinolines; Tissue Culture Techniques; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival; Temozolomide; Treatment Outcome | 2009 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Retrospective Studies; Survival Rate; Temozolomide | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome; Waiting Lists | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Senescence; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Dacarbazine; DNA Methylation; Glioma; Heterochromatin; Histones; Humans; Methyl-CpG-Binding Protein 2; Temozolomide | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Temozolomide | 2010 |
In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Dacarbazine; Genetic Therapy; Genetic Vectors; Guanine; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Lentivirus; Macaca mulatta; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2009 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Genomic Imprinting; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Therapy, Combination; Female; Glioma; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biocompatible Materials; Carmustine; Dacarbazine; Decanoic Acids; Drug Carriers; Humans; Polyesters; Temozolomide; Treatment Outcome | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA, Complementary; Exons; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Female; France; Glioma; Humans; Male; Middle Aged; Polyesters; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Craniotomy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Retreatment; Temozolomide; Treatment Outcome | 2010 |
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Guanine; Humans; Hydrazines; Mice; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Temozolomide | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nervous System Diseases; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Linear Models; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Reoperation; Retreatment; Salvage Therapy; Temozolomide; Time Factors; Young Adult | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Hospitals; Humans; Incidence; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Thrombocytopenia; Tumor Burden; Tumor Suppressor Proteins; Young Adult | 2012 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2011 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic Therapy; Glioblastoma; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lentivirus; Temozolomide; Transplantation Conditioning; Tumor Suppressor Proteins | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Delayed-Action Preparations; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Temozolomide; Treatment Outcome | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dacarbazine; Eukaryotic Translation Initiation Factor 5A; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Lysine; Male; Mixed Function Oxygenases; Molecular Targeted Therapy; Neoplasm Grading; Oxidoreductases Acting on CH-NH Group Donors; Peptide Initiation Factors; RNA-Binding Proteins; Temozolomide | 2012 |
F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carmustine; Cell Survival; Cloning, Molecular; Cytoprotection; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Genetic Vectors; Hematopoietic Stem Cells; HL-60 Cells; Humans; K562 Cells; Lentivirus; Nimustine; Paclitaxel; Peptides; Real-Time Polymerase Chain Reaction; Temozolomide; Transgenes; Tumor Suppressor Proteins | 2012 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Nitric Oxide; O(6)-Methylguanine-DNA Methyltransferase; Scorpion Venoms; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Glioblastoma; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Hydrocarbons, Brominated; Hypoxia; Mice; Mice, SCID; Mitochondria; Neoplastic Stem Cells; Propionates; Temozolomide | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Implants; Feasibility Studies; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Postoperative Complications; Prospective Studies; Supratentorial Neoplasms; Survival Analysis; Survival Rate; Temozolomide | 2013 |
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Topics: Aminooxyacetic Acid; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glutamine; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Mutation; Oxidative Stress; RNA, Small Interfering; Signal Transduction; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Glioblastoma; Guanosine; Humans; Methylation; Middle Aged; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Flow Cytometry; Glioblastoma; HEK293 Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Binding; Proto-Oncogene Proteins c-cbl; Rho Guanine Nucleotide Exchange Factors; RNA Interference; Signal Transduction; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Glioma; Humans; Neoplasm Grading; Temozolomide | 2014 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mice, Inbred C57BL; MutS Homolog 2 Protein; Radiation, Ionizing; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Carmustine; Dacarbazine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Inhibitory Concentration 50; Oxidative Stress; Rats; Temozolomide | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Japan; Karnofsky Performance Status; Male; Middle Aged; Polyesters; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Female; Glioblastoma; Humans; Luteolin; Mice; Mice, Nude; MicroRNAs; Signal Transduction; Silybin; Silymarin; Sirolimus; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Nuclear Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide; Transcription Factors | 2016 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Female; Glioma; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Serbia; Survival Analysis; Temozolomide | 2017 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cysts; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Implants; Drug Synergism; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Postoperative Hemorrhage; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Chromosome Duplication; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Metabolic Networks and Pathways; Metabolome; Models, Biological; Neoplasm Proteins; Temozolomide; Tumor Suppressor Proteins | 2018 |
Impact of human cytomegalovirus on glioblastoma cell viability and chemotherapy treatment.
Topics: Antineoplastic Agents; Carmustine; Cell Line, Tumor; Cell Survival; Cytomegalovirus; Gene Expression Regulation, Viral; Glioblastoma; Humans; Temozolomide; Viral Proteins | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Carmustine; Cell Line, Tumor; Dronabinol; Glioma; Heterografts; Humans; Male; Mice, Nude; Temozolomide | 2018 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; HEK293 Cells; Humans; Mice; Mice, Nude; Survival Rate; Temozolomide; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Preparations; Drug Implants; Female; Glioblastoma; Polyesters; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Inbred F344; Temozolomide | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Karnofsky Performance Status; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Neoplasms, Neuroepithelial; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2019 |
MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Computational Biology; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Code; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2021 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Temozolomide | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local; Reactive Oxygen Species; Temozolomide | 2022 |
CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carmustine; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lomustine; Neoplasm Proteins; Temozolomide | 2022 |
Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture.
Topics: Carmustine; Cell Culture Techniques; Glioblastoma; Humans; Hydrogels; Lab-On-A-Chip Devices; Polyethylene Glycols; Siloxanes; Temozolomide; Tumor Microenvironment | 2022 |